ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed…
<!-- Name:DistributionId Value:8786071 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
ALX
ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical…
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies…
ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc…
SOUTH SAN FRANCISCO, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies…
ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of…
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies…
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of…
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies…
ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the…
SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies…
ALX Oncology to Participate in the Jefferies 2022 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies…
ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the…
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies…
ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of…
-- Complete remissions with cytogenetic responses, hematologic improvement, and transfusion independence were observed in patients with previously untreated higher-risk MDS -- Objective…